These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16981821)

  • 1. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma.
    Egloff AM; Grandis J
    Expert Opin Ther Targets; 2006 Oct; 10(5):639-47. PubMed ID: 16981821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignancies of the head and neck: the role for molecular targeted agents.
    Agulnik M
    Expert Opin Ther Targets; 2007 Feb; 11(2):207-17. PubMed ID: 17227235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of molecular targeted therapy with radiation in head and neck cancer.
    Du Y; Peyser ND; Grandis JR
    Pharmacol Ther; 2014 Apr; 142(1):88-98. PubMed ID: 24280066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.
    Egloff AM; Grandis JR
    Semin Oncol; 2008 Jun; 35(3):286-97. PubMed ID: 18544443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
    Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL
    Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
    Song Q; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer.
    Byeon HK; Ku M; Yang J
    Exp Mol Med; 2019 Jan; 51(1):1-14. PubMed ID: 30700700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.
    Boeckx C; Baay M; Wouters A; Specenier P; Vermorken JB; Peeters M; Lardon F
    Oncologist; 2013; 18(7):850-64. PubMed ID: 23821327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells.
    Suzuki S; Ishikawa K
    Int J Oncol; 2014 Mar; 44(3):912-7. PubMed ID: 24379084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.